Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
4 authors.
Elizabeth HeadDepartment of Pathology & Laboratory Medicine, University of California, Irvine, California, USA.
Ann CohenDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Juan ForteaMemory Unit, Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau, Barcelona, Spain.
Eimear McGlincheyTrinity Centre for Ageing and Intellectual Disability, School of Nursing and Midwifery, Trinity College Dublin, Dublin, Ireland.
Funding
Project 3: Biomarkers for DS Clinical TrialsU19AG068054 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTIAN, BRADLEY T, HANDEN, BENJAMIN L · 2020 to 2025
$103.7M
The Alzheimer's Disease Research Center at the University of California, IrvineP30AG066519 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI Mathew Mark Blurton-Jones · 2020 to 2026
$27.9M
DS-ARC: A Remote Digital Cognitive Assessment for Down Syndrome-Associated Alzheimer's DiseaseR01AG081394 · NIA · WASHINGTON UNIVERSITY · PI Jason J Hassenstab · 2023 to 2026
$6.0M
The Role of Inflammation and NGF Dysfunction in the Evolution of Alzheimer Disease Pathology in Down Syndrome-RevisionRF1AG056850 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI BUSCIGLIO, JORGE A, CUELLO, A CLAUDIO · 2018 to 2020
$5.9M
Clinical trials to prevent Alzheimer's Disease in Down SyndromeR61AG066543 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI RAFII, MICHAEL S · 2019 to 2020
$5.6M
Tau pathology in Down syndrome and Alzheimer'sRF1AG061566 · NIA · UNIVERSITY OF DENVER (COLORADO SEMINARY) · PI GRANHOLM-BENTLEY, ANN-CHARLOTTE ESTHER, MARGITTAI, MARTIN · 2019 to 2019
$3.4M
Cerebrovascular contributions to Alzheimer's disease in adults with Down SyndromeRF1AG079519 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BRICKMAN, ADAM M, HEAD, ELIZABETH · 2022 to 2022
$3.1M
Biological Correlates of Alzheimer in Down Syndrome.R21AG056974 · NIA · UNIVERSITY OF DENVER (COLORADO SEMINARY) · PI GRANHOLM-BENTLEY, ANN-CHARLOTTE ESTHER · 2017 to 2018
$414k
Alzheimer Association HPE-ADRD 24HPE1284307Carlos III Health Institute INT21/00073Carlos III Health Institute PI20/01473Carlos III Health Institute PI23/01786Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) Program 1Department de Salut de la Generalitat de Catalunya SLT006/17/00119Fondo de Investigaciones SanitarioFondo Europeo de Desarrollo RegionalFundaciónHorizon 2020-Research and Innovation Framework Programme H2020-SC1-BHC-2018-2020NIA NIH HHS P30 AG066519NIA NIH HHS R01 AG081394NIA NIH HHS R21 AG056974NIA NIH HHS R61 AG066543NIA NIH HHS RF1 AG056850NIA NIH HHS RF1 AG061566NIA NIH HHS RF1 AG079519NIA NIH HHS U19 AG068054NIH/NIA 1R01AG081394NIH/NIA P30AG066519NIH/NIA R01AG056850NIH/NIA R01AG061566NIH/NIA R21AG056974NIH/NIA R61AG066543NIH/NIA RF1AG079519NIH/NIA U19AG068054Tatiana Pérez de Guzmán el Bueno IIBSP-DOW-2020-151
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Novel insights into Alzheimer's disease through the study of individuals with Down syndrome. · full record | Socratic